ATE171069T1 - Transdermale verhütungsmittelformulierung, verfahren und vorrichtung - Google Patents

Transdermale verhütungsmittelformulierung, verfahren und vorrichtung

Info

Publication number
ATE171069T1
ATE171069T1 AT92900228T AT92900228T ATE171069T1 AT E171069 T1 ATE171069 T1 AT E171069T1 AT 92900228 T AT92900228 T AT 92900228T AT 92900228 T AT92900228 T AT 92900228T AT E171069 T1 ATE171069 T1 AT E171069T1
Authority
AT
Austria
Prior art keywords
contraceptive formulation
transdermal contraceptive
transdermal
formulation
progesterone
Prior art date
Application number
AT92900228T
Other languages
English (en)
Inventor
Robert M Gale
Diane E Nedberge
Linda E Atkinson
Original Assignee
Population Council Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Population Council Inc filed Critical Population Council Inc
Application granted granted Critical
Publication of ATE171069T1 publication Critical patent/ATE171069T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Semiconductor Lasers (AREA)
  • Vending Machines For Individual Products (AREA)
  • Steroid Compounds (AREA)
AT92900228T 1990-10-29 1991-10-25 Transdermale verhütungsmittelformulierung, verfahren und vorrichtung ATE171069T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/605,726 US5122382A (en) 1990-10-29 1990-10-29 Transdermal contraceptive formulations, methods and devices

Publications (1)

Publication Number Publication Date
ATE171069T1 true ATE171069T1 (de) 1998-10-15

Family

ID=24424948

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92900228T ATE171069T1 (de) 1990-10-29 1991-10-25 Transdermale verhütungsmittelformulierung, verfahren und vorrichtung

Country Status (16)

Country Link
US (1) US5122382A (de)
EP (1) EP0577602B1 (de)
JP (1) JP2975684B2 (de)
AT (1) ATE171069T1 (de)
AU (1) AU9041991A (de)
CA (1) CA2088778C (de)
DE (1) DE69130232T2 (de)
DK (1) DK0577602T3 (de)
ES (1) ES2123547T3 (de)
IE (1) IE913741A1 (de)
MX (1) MX9101784A (de)
NO (1) NO303527B1 (de)
NZ (1) NZ240361A (de)
PT (1) PT99340B (de)
WO (1) WO1992007589A1 (de)
ZA (1) ZA918531B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US5256421A (en) * 1987-09-24 1993-10-26 Jencap Research Ltd. Hormone preparation and method
US5276022A (en) * 1987-09-24 1994-01-04 Jencap Research Ltd. Hormone preparation and method
DK0754456T3 (da) * 1990-06-01 2002-11-11 Population Council Inc Forberedelse af sammensætninger der omfatter ST1435 til topisk anvendelse
US5320850A (en) * 1990-10-29 1994-06-14 Alza Corporation Transdermal delivery of the gestogen ST-1435 and devices therefor
JP2960832B2 (ja) * 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト エストラジオールの投与システム
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
MX9303557A (es) * 1992-08-06 1994-03-31 Beta Pharm Co Metodo para la administracion de un antiandrogeno, en particular, espironolactona, a traves de la piel.
CA2114968A1 (en) * 1993-02-25 1994-08-26 John Wille Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
NZ274711A (en) * 1993-09-29 1996-11-26 Alza Corp Composition for administration of active agent by application to a body surface or membrane comprising permeability enhancing amount of monoglyceride(s) and lactate ester(s)
DE4400770C1 (de) * 1994-01-13 1995-02-02 Lohmann Therapie Syst Lts Wirkstoffhaltiges Pflaster zur Abgabe von Estradiol mit mindestens einem Penetrationsverstärker, Verfahren zu seiner Herstellung und seine Verwendung
DE19513662A1 (de) * 1995-04-08 1996-10-10 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
US5882676A (en) * 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
AU726283B2 (en) * 1995-06-28 2000-11-02 Schering Aktiengesellschaft Pharmaceutical combined preparations, kit and method for hormonal contraception
FR2739032B1 (fr) * 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base d'eva, procede de preparation et utilisation en therapeutique
US5730721A (en) * 1996-01-25 1998-03-24 Vesture Corporation Medical applicator and method
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US6267984B1 (en) 1997-12-22 2001-07-31 Alza Corporation Skin permeation enhancer compositions comprising a monoglyceride and ethyl palmitate
US6699497B1 (en) * 1998-07-24 2004-03-02 Alza Corporation Formulations for the transdermal administration of fenoldopam
CN101693023A (zh) 1998-12-18 2010-04-14 阿尔扎有限公司 透明的透皮烟碱输送装置
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
WO2004058043A2 (en) * 2002-12-30 2004-07-15 Given Imaging Ltd. Method for in vivo sensing
US20040258742A1 (en) * 2003-04-11 2004-12-23 Van Osdol William Woodson Transdermal administration of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidines
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ES2379117T3 (es) 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP2010521496A (ja) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． キラル精製置換ベンゾチアゾールジアミンの合成
WO2009009651A1 (en) * 2007-07-10 2009-01-15 Agile Therapeutics, Inc. Dermal delivery device with ultrasonic weld
WO2009009649A1 (en) 2007-07-10 2009-01-15 Agile Therapeutics, Inc. Dermal delivery device with in situ seal
CA2734491A1 (en) 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
AU2010262970A1 (en) * 2009-06-19 2012-01-12 Knopp Neurosciences, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
EP2512486B1 (de) * 2009-12-17 2017-06-28 The Population Council, Inc. Nestorone®/estradiol transdermales gel
WO2012096866A2 (en) 2011-01-10 2012-07-19 Inverseon, Inc. Use of beta-adrenergic inverse agonists for smoking cessation
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
WO2013177570A1 (en) 2012-05-25 2013-11-28 Terapio Corporation Methods of preventing or treating disease of the central nervous system using rlip76
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
CN105764507B (zh) 2013-07-12 2019-07-19 诺普生物科学有限责任公司 治疗升高的嗜酸性粒细胞和/或嗜碱性粒细胞的水平
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
EP3033081B1 (de) 2013-08-13 2021-05-12 Knopp Biosciences LLC Zusammensetzungen und verfahren zur behandlung von chronischer nesselsucht
EP3046544A4 (de) 2013-09-17 2017-03-22 Terapio Corporation Verfahren zur prävention oder behandlung von mucositis mit rlip76

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800038A (en) * 1972-04-21 1974-03-26 Biolog Concepts Inc Uterine administraton of eutectic solid solutions of steroid hormones in a steroidal lipid carrier
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
CH674618A5 (de) * 1987-04-02 1990-06-29 Ciba Geigy Ag

Also Published As

Publication number Publication date
NO303527B1 (no) 1998-07-27
DE69130232D1 (de) 1998-10-22
DE69130232T2 (de) 1999-04-08
NO931209D0 (no) 1993-03-31
EP0577602B1 (de) 1998-09-16
PT99340B (pt) 1999-02-26
NZ240361A (en) 1995-07-26
NO931209L (no) 1993-04-26
MX9101784A (es) 1992-06-05
JPH06502429A (ja) 1994-03-17
ZA918531B (en) 1992-08-26
IE913741A1 (en) 1992-05-22
WO1992007589A1 (en) 1992-05-14
US5122382A (en) 1992-06-16
CA2088778C (en) 2001-08-14
AU9041991A (en) 1992-05-26
DK0577602T3 (da) 1999-06-14
JP2975684B2 (ja) 1999-11-10
PT99340A (pt) 1992-09-30
EP0577602A1 (de) 1994-01-12
CA2088778A1 (en) 1992-04-30
ES2123547T3 (es) 1999-01-16

Similar Documents

Publication Publication Date Title
ATE171069T1 (de) Transdermale verhütungsmittelformulierung, verfahren und vorrichtung
ES2132645T3 (es) Uso en una composicion farmaceutica.
ATE293979T1 (de) Pharmazeutische zusammensetzungen enthaltend syntethisch natürliche progesteron und estradiol und verfahren zur herstellung derselben
DE68919194D1 (de) Hydrogenierte Dien-copolymer-Zusammensetzung und Verfahren zu deren Herstellung.
DE69109213D1 (de) Verfahren und Vorrichtung zur Erzeugung von Röntgenstrahlen.
ATE203667T1 (de) Transdermales system in form eines pflasters mit einem tamoxifen-derivat
ATE258068T1 (de) Zusammensetzung, vorrichtung und verfahren zur verbesserten elektrotransport-wirkstoffabgabe
DE68915007D1 (de) Verfahren und Gerät zur Elektronenstrahlbelichtung.
DE69115150D1 (de) Verfahren und Gerät zur Bestrahlung mittels niederenergetischer Elektronen.
DE59008902D1 (de) Verfahren und Vorrichtung zur Erstellung von medizinischen, insbesondere zahnmedizinischen Prothetik- Passkörpern.
DK0472645T3 (da) Osmotisk doseringsform
DE59105635D1 (de) Vorrichtung und verfahren zur materialverdampfung.
DE68900892D1 (de) Zusammenstellung zur behandlung der osteoporose beim menschen.
GR900100489A (el) Συνθέσεις χρήσιμοι ως αντισυλληπτικά για άνδρες.
DE69114187D1 (de) Vorrichtung und Verfahren zur Herstellung von Halbleitereinrichtungen.
DE3667537D1 (de) Verfahren zur genauen nachlaufspreizung und sturz an kraftfahrzeugen.
DE69015616D1 (de) Verfahren und gerät bezüglich ionenimplantierung.
MX9100886A (es) Activador de plasminogeno hibrido,procedimiento para su preparacion y composiciones farmaceuticas que lo contienen
DE69110014D1 (de) Verfahren und Vorrichtung zur Herstellung von Zigaretten.
DE69011299D1 (de) Verfahren und Vorrichtung zur Filmschneide-Positionsprüfung.
NO931208L (no) Formuleringer for transdermale kontraseptiver, samt fremgangsmaater og innretninger for tilfoersel av slike
ATE141523T1 (de) Spermicides beschichtungsmittel
DE58905335D1 (de) Verfahren und vorrichtung zur notlauf-kraftstoffeinstellung.
NL194960B (nl) Werkwijze voor het bereiden van mutantstammen van Bordetella bronchiseptica en daarop gebaseerd levend verzwakt vaccin.
DE68902429D1 (de) Brotaufstrich, verfahren und vorrichtung zur rahm- und brotaufstrichbehandlung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time